For the quarter ended December 2025, Apellis Pharmaceuticals, Inc. (APLS) reported revenue of $199.91 million, down 5.9% over the same period last year. EPS came in at $0.47, compared to -$0.29 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $194.37 million, representing a surprise of +2.85%. The company delivered an EPS surprise of +219.14%, with the consensus EPS estimate being -$0.40.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Apellis Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Product revenue, net: $190.34 million versus $187.07 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -0.4% change.
- Revenue- Licensing and other revenue: $9.57 million versus the nine-analyst average estimate of $7.31 million. The reported number represents a year-over-year change of -55.2%.
- Product Revenue- EMPAVELI: $35.1 million versus the eight-analyst average estimate of $28.51 million. The reported number represents a year-over-year change of +50.3%.
- Product Revenue- SYFOVRE: $155.2 million versus the eight-analyst average estimate of $154.18 million. The reported number represents a year-over-year change of -7.5%.
View all Key Company Metrics for Apellis Pharmaceuticals here>>>
Shares of Apellis Pharmaceuticals have returned +2.2% over the past month versus the Zacks S&P 500 composite's -1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Apellis Pharmaceuticals, Inc. (APLS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
